Dermal Fillers in Dallas

Getting filler is a medical procedure, and the FDA says it should not be treated as a cosmetic service (FDA). The product itself is a gel or suspension injected beneath the skin to smooth wrinkles and folds or to add volume in the lips, cheeks, chin and the backs of the hands (FDA). For that reason, the safety research and the Texas injector rules get as much space on this page as the materials, the approved brands and pricing around Dallas.

The materials

Four filler materials

Fillers fall into four material groups. Most are temporary because the body breaks them down over time, and the FDA has approved just one product made of a material that stays in the body (FDA).

Hyaluronic acid (HA). Skin and cartilage contain this sugar naturally. As a gel it absorbs water and expands, which is what fills the treated spot, and manufacturers cross-link some HA chemically to make it last longer. The FDA’s general estimate is about 6 to 12 months (FDA), although particular products can outlast it in particular areas: in the cheek study behind Juvéderm Voluma XC, 67.1% of patients followed to 24 months still had at least a 1-point improvement (Allergan’s Voluma XC directions). Because the enzyme hyaluronidase splits hyaluronic acid, an injection of it can break down HA filler (Hylenex label).

Calcium hydroxylapatite (CaHA). Radiesse is made from this mineral, the same one found in bone and teeth, delivered as particles suspended in gel. The FDA estimates it lasts about 18 months. It also shows up on x-rays and can obscure the tissue beneath it (FDA).

Poly-L-lactic acid (PLLA). Sculptra is this synthetic, biodegradable polymer, injected in a series of sessions over several months. The FDA says its effect develops over several weeks and may last as long as 2 years (FDA). A 2022 review groups PLLA and CaHA as biostimulatory fillers, meaning they trigger a controlled foreign-body reaction that leads to new collagen (Haddad 2022 review).

Polymethylmethacrylate (PMMA). Bellafill uses tiny PMMA beads that are never absorbed, carried in a gel that contains bovine (cow) collagen (FDA). The FDA advises allergy testing before using fillers that contain animal-derived materials such as bovine collagen (FDA).

Hyaluronidase works only on hyaluronic acid, so CaHA, PLLA and PMMA do not dissolve with it. The FDA warns that taking filler out can be difficult or impossible, particularly with permanent fillers and with fillers made of materials unlike HA (FDA).

Brands

FDA-approved filler brands and their areas

Every dermal filler needs its own FDA premarket approval (PMA), and that approval lists the areas and uses it covers (FDA). Dates here come from the FDA PMA database. Ask your injector which product they will use and what its approval covers.

Hyaluronic acid brands

Juvéderm (PMA held by Allergan)

• Voluma XC: cheek augmentation, 2013 (FDA approval record); chin, 2020 (FDA approval record); temples, 2023 (FDA approval record).
• Volbella XC: lips and perioral lines, 2016 (FDA approval record); under-eye hollows, 2021 (FDA approval record).
• Vollure XC: facial wrinkles and folds, 2017 (FDA approval record).
• Volux XC: jawline definition, 2022 (FDA approval record).
• SkinVive: cheek skin smoothness, 2023 (FDA approval record).

Restylane (PMA held by Q-Med AB). The original Restylane gained approval in 2003 (FDA approval record). Later approvals:

• Silk: lips, 2014 (FDA approval record).
• Lyft: 2015 (FDA approval record); back of the hand, 2018 (FDA approval record); chin, 2025 (FDA approval record).
• Refyne and Defyne: facial wrinkles and folds, 2016 (FDA approval record).
• Kysse: lips, 2020 (FDA approval record).
• Defyne: chin, 2021 (FDA approval record).
• Contour: cheeks, 2021 (FDA approval record); temples, 2026 (FDA approval record).
• Eyelight: under-eye hollows, 2023 (FDA approval record).

RHA Collection (PMA held by Teoxane)

• RHA 2, RHA 3 and RHA 4: dynamic facial wrinkles and folds, 2017 (FDA approval record).
• RHA Redensity: perioral lines, 2021 (FDA approval record).
• RHA 3: lips, 2023 (FDA approval record).
• RHA 4 and RHA Dynamic Volume: cheek augmentation and midface contour, September 2025 (FDA approval record).

Belotero (PMA held by Merz). Belotero Balance received approval in 2011 for facial wrinkles and folds, nasolabial folds included (FDA approval record). In 2026, Belotero Volume (+) Lidocaine was approved for the midface in May (FDA approval record), and Belotero Intense (+) Lidocaine for the lips in July (FDA approval record).

Evolysse (PMA held by Symatese). The FDA approved two products, Evolysse Smooth and Evolysse Form, in February 2025; both treat dynamic wrinkles and folds of the face that are moderate to severe (FDA approval record).

saypha (PMA held by Croma-Pharma). The FDA approved saypha MagIQ in September 2025 for facial wrinkles and folds, nasolabial folds among them (FDA approval record), and saypha ChIQ in June 2026 for cheek augmentation and midface volume (FDA approval record).

Brands made from other materials

Radiesse (PMA held by Merz), a calcium hydroxylapatite filler, was approved in 2006 for moderate to severe facial wrinkles and folds (FDA approval record). A separate approval covers facial fat loss in people with HIV (FDA approval record). The back of the hand was added in 2015 (FDA approval record), and in 2021 Radiesse (+) was approved for jawline contour (FDA approval record).

Sculptra (PMA held by Q-Med AB), a poly-L-lactic acid filler, received its first approval in 2004 for facial fat loss in people with HIV (FDA approval record). Sculptra Aesthetic followed in 2009 for contour deficiencies of the nasolabial folds and other facial wrinkles in people with healthy immune systems (FDA approval record).

Bellafill, the PMMA filler, holds approval for nasolabial folds. Since December 2014 it has also been approved to treat atrophic acne scars of the cheek, moderate to severe, in patients over the age of 21 (FDA approval record).

The FDA warns that unapproved versions of Juvéderm, including Juvéderm Ultra 2, 3 and 4, have been sold in the U.S., some of them online, and should not be used (FDA). It also tells consumers not to buy filler online and notes that no needle-free injection device is approved for dermal filler (FDA).

The appointment

The visit and the recovery period

Filler is placed with either a needle or a blunt-tip cannula. Some products, Voluma XC among them, contain the numbing medicine lidocaine (Allergan’s Voluma XC directions). Ask the practice how long your appointment will take and how swollen you are likely to be.

1. First 24 hours

   The Juvéderm Voluma XC label tells patients to skip strenuous exercise and extensive sun or heat during this period, and to apply an ice pack briefly for swelling (Allergan's Voluma XC directions). Other products have their own instructions, so follow the ones for yours.

2. Following weeks

   Per the FDA, bruising, swelling and most other side effects start shortly after injection, and many go away over days or weeks (FDA). In the Voluma XC cheek study, most treatment-site reactions were mild or moderate, with a duration of 2 to 4 weeks, and the moderate or severe ones took a median of 6 days to clear completely (Allergan's Voluma XC directions).

3. Longer term

   By the FDA's estimates, results fade after roughly 6 to 12 months with HA, roughly 18 months with CaHA and as long as 2 years with PLLA, while PMMA stays permanently (FDA). The FDA adds that certain side effects may not appear until weeks, months or years later (FDA).

Safety

Vascular occlusion and blindness

Among filler risks, the FDA ranks unintentional injection into a blood vessel as the most concerning. Filler in a vessel can block blood flow to the tissue it supplies. The FDA calls this unlikely but warns the results can be serious and lasting: tissue death, vision problems including blindness, and stroke (FDA).

The published numbers

• Frequency: A survey of 370 dermatologists spanning 10 years and roughly 1.7 million syringes found 1 occlusion per 6,410 one-milliliter syringes injected by needle and 1 per 40,882 injected by cannula. Of those occlusions, 85% left no long-term effects (Alam 2021 survey).
• Reported vision loss: The 2024 review identified 365 published cases of partial or complete vision loss after filler, reported from September 2018 through March 2023. The authors’ two prior reviews had counted 98 cases (2015) and 48 additional cases (2019) (Doyon 2024 review).
• Where it happened: The nose accounted for the most cases (40.6%), ahead of the forehead (27.7%) and the glabella, between the brows (19.0%). HA was the filler involved in 79.6% (Doyon 2024 review).
• Recovery: An outcome was reported for 318 cases. Full vision returned in 6.0%, partial improvement in 25.8%, and no recovery in 68.2%. Improvement was linked to vision that was partly preserved at onset, and no treatment had a significant association with improvement (Doyon 2024 review).

Symptoms that need help right away

The FDA says to seek immediate medical help, during treatment or soon after, for unusual pain, vision changes, or white, gray or blue skin near the injection site. Stroke signs call for the same urgency: weakness or numbness of the face, arms or legs, a face that droops, suddenly struggling to speak, difficulty walking, confusion, dizziness or a severe headache (FDA).

How a practice prepares

When skin blanches and does not regain its normal color, the Voluma XC label points injectors to the guidelines of the American Society for Dermatologic Surgery, among them injecting hyaluronidase. The label further asks injectors to have supplies ready at hand and to identify a local ophthalmologist they could call for an eye-related event (Allergan’s Voluma XC directions). Dissolving filler is not an approved use of hyaluronidase. The FDA approved it for urography and as an aid to absorbing fluids and drugs (Hylenex label). It does nothing to Radiesse, Sculptra or Bellafill, none of which is HA.

For an HA filler, ask whether the practice has hyaluronidase on site and what steps it takes if it suspects a vessel injection.

Newer research

Chin bone resorption

In a 2020 study, researchers compared CT scans from 80 patients who had HA filler in the chin with scans from 80 matched controls and found significantly thinner chin bone in the filler group. Bone loss was greater with 1 mL or more per session than with smaller amounts, while neither how many injections patients had nor the spacing between them mattered significantly. The authors reported no loss in appearance, but advised caution with large HA volumes in the chin and recommended warning patients about this complication before treatment (Guo 2020 study). The study was preliminary and retrospective, and it involved Asian patients at one hospital.

Safety

Common reactions and other cautions

The FDA lists bruising, redness, swelling, pain, tenderness, itching and rash as common risks, and notes that filler in the back of the hand can make daily tasks difficult (FDA). One label gives these rates:

Source: Allergan’s Voluma XC directions. Products and areas differ, so ask for the label of the filler you will get.

Less common, per the FDA: inflammation near the site after a vaccination, dental work, or a viral or bacterial illness; nodules or granulomas that may require injections, oral antibiotics or surgery; infection; open or draining wounds; and allergic reactions. Rare reports to the FDA: death, anaphylactic shock, permanent hard nodules, filler that ruptures or leaks, and filler that migrates from its placement (FDA).

Pregnancy and breastfeeding. Whether fillers are safe in pregnancy or while breastfeeding is unknown, according to the FDA (FDA).

Other cautions on the Voluma XC label: it should not be used by anyone with anaphylaxis or multiple severe allergies in their history, or with an allergy to lidocaine or gram-positive bacterial proteins. Active infection or inflammation means postponing treatment. Immunosuppressive therapy calls for caution, and warfarin, aspirin and NSAIDs can increase bruising or bleeding (Allergan’s Voluma XC directions).

Cost

Filler pricing in Dallas

Your price depends on the spa, the brand and the syringe count, so request a quote from each practice. The area pages on this site show the national average below.

The American Society of Plastic Surgeons reports $715 as the national average for hyaluronic acid filler (ASPS). It reflects plastic surgeons’ fees nationwide, not what Dallas med spas charge. On any quote, confirm the product and the number of syringes.

Before you book

Picking an injector

The FDA’s advice is to pick a licensed provider who is trained to inject filler and experienced in plastic surgery or dermatology, and to ask how they trained and how much face and hand injection they have done (FDA).

Texas rules on who injects

In Texas, cosmetic injection is a nonsurgical medical cosmetic procedure (Tex. Admin. Code §169.25), governed by Texas Medical Board Chapter 169 rules in effect since January 9, 2025 (Texas Medical Board). If a physician delegates the injection:

• A practitioner-patient relationship must exist before the procedure, established by a physician or by a PA or APRN under that physician’s delegation (Tex. Admin. Code §169.26). The industry calls this a “good faith exam,” a term the rule does not use.
• The injector must be trained in the procedure, its contraindications, and how to recognize and manage complications (Tex. Admin. Code §169.26).
• Emergency backup has two parts. A physician, PA or APRN has to be onsite or immediately available to consult, and someone with basic life support training has to stay on the premises the entire time you are (Tex. Admin. Code §169.26).
• There must be a written order (Tex. Admin. Code §169.27), and the injector must sign and date a written protocol (Tex. Admin. Code §169.26).
• Each public area and each treatment room must display the delegating physician’s name and Texas license number (Tex. Admin. Code §169.28).

Estheticians may not inject filler. According to TDLR, injectables and fillers are not part of an esthetician’s facial services, and filler requires a licensed physician’s order and delegation (TDLR).

2025 Texas legislation

• HB 3749, on elective intravenous (IV) therapy, became law with a June 20, 2025 signature and an effective date of September 1, 2025 (Texas Legislature Online). This bill does not govern filler; the Chapter 169 rules from the Texas Medical Board, covered above, do.
• SB 378, on certain prohibited practices by barbers and cosmetologists, did not become law: the Governor vetoed it on June 2, 2025 (Texas Legislature Online).

Checking licenses

1. Physicians and PAs: the Texas Medical Board’s Look Up a License search shows whether a license is active and lists any disciplinary actions.
2. Board certification: ask the physician to name the certifying specialty board, then check with that board directly.
3. RNs and APRNs: verify the license through the Texas Board of Nursing.

Consultation questions

• What product would you choose for my goals, and why? Does its FDA approval cover this area?
• Which physician delegates your injections, and where in the office are that physician’s name and license number displayed?
• Before treatment, who establishes my practitioner-patient relationship (what spas call the good faith exam)?
• Is hyaluronidase kept in the office?
• What will you do if I show signs of a blocked vessel, like pain, white or blue skin, or vision changes?
• How many times have you personally done this procedure?
• Can I see before-and-after photos of patients you treated?
• May I read the patient labeling for the product you plan to use?

Red flags

• Nobody can tell you who the delegating physician is
• The physician’s name and license number are not on display, as Texas requires (Tex. Admin. Code §169.28)
• You are treated before a practitioner-patient relationship is established (Tex. Admin. Code §169.26)
• The person injecting is an esthetician (TDLR)
• The filler came from an online seller, or a needle-free device is used to inject it (FDA)
• The practice offers HA filler but keeps no hyaluronidase on site